Indication
In combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
Medicine details
- Medicine name:
- talazoparib (Talzenna)
- SMC ID:
- SMC2753
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Publication due date:
- 10 March 2025